Hepatitis Monthly

Published by: Kowsar

Skin Adverse Events During Dual and Triple Therapy for HCV-Related Cirrhosis

Alessandro Federico 1 , * , Dolores Sgambato 1 , Gaetano Cotticelli 1 , Antonietta Gerarda Gravina 1 , Marcello Dallio 1 , Filippo Beneduce 1 , Eleonora Ruocco 2 , Marco Romano 1 and Carmela Loguercio 1
Authors Information
1 Department of Clinical and Experimental Medicine, Gastroenterology Unit, Second University of Naples, Naples, Italy
2 Department of Dermatology, Second University of Naples, Naples, Italy
Article information
  • Hepatitis Monthly: March 01, 2014, 14 (3); e16632
  • Published Online: March 11, 2014
  • Article Type: Case Report
  • Received: December 5, 2013
  • Revised: December 19, 2013
  • Accepted: December 30, 2013
  • DOI: 10.5812/hepatmon.16632

To Cite: Federico A, Sgambato D, Cotticelli G, Gravina A G, Dallio M, et al. Skin Adverse Events During Dual and Triple Therapy for HCV-Related Cirrhosis, Hepat Mon. 2014 ; 14(3):e16632. doi: 10.5812/hepatmon.16632.

Copyright © 2014, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Conclusions
  • 1. Lubbe J, Kerl K, Negro F, Saurat JH. Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases. Br J Dermatol. 2005; 153(5): 1088-90[DOI][PubMed]
  • 2. Lübbe J. Dermatological side effects. Hot Topics in Viral Hep. 2008; 9: 29-35
  • 3. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25): 2405-16[DOI][PubMed]
  • 4. Cacoub P, Bourliere M, Lubbe J, Dupin N, Buggisch P, Dusheiko G, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol. 2012; 56(2): 455-63[DOI][PubMed]
  • 5. Hashimoto Y, Kanto H, Itoh M. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus. J Dermatol. 2007; 34(8): 577-82[DOI][PubMed]
  • 6. Manjon-Haces JA, Vazquez-Lopez F, Gomez-Diez S, Hidalgo-Garcia A, Perez-Alvarez R, Soler-Sanchez T, et al. Adverse cutaneous reactions to interferon alfa-2b plus ribavirin therapy in patients with chronic hepatitis C virus. Acta Derm Venereol. 2001; 81(3): 223[PubMed]
  • 7. Dereure O, Raison-Peyron N, Larrey D, Blanc F, Guilhou JJ. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol. 2002; 147(6): 1142-6[PubMed]
  • 8. Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol. 2009; 23(10): 677-83[PubMed]
  • 9. Picard O, Cacoub P. Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management. Clin Res Hepatol Gastroenterol. 2012; 36(5): 437-40[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments